OpGen says Acuitas panel shows potential to reduce total time to therapy
OpGen announced the presentation of data obtained from the first multisite assessment evaluating the potential clinical utility of its Acuitas AMR Gene Panel using clinical samples. The study tested 531 remnant urine specimens from Beth Israel Deaconess Medical Center, Geisinger, and Intermountain Healthcare with the Acuitas AMR Gene Panel, to detect five pathogens and 47 antibiotic resistance genes common to urinary tract infections. Results for the Acuitas AMR Gene Panel were produced in less than three hours. These data were presented on June 22 by Geisinger researchers at ASM Microbe 2019 in a poster titled "Verification of Real Time PCR for the Detection of Antibiotic-Resistance Markers and Semi-Quantitation of Urinary Tract Pathogens from Urine Samples." For the two most prevalent microbial species, E. coli and K. pneumoniae, the Acuitas Gene Panel had a total agreement of 96% and 97%, respectively, for pathogen detection, compared to MALDI-ToF mass spectrometry. Acuitas Lighthouse predictions for phenotypic Antimicrobial Susceptibility Testing showed 93% total agreement for E. coli and 92% total agreement for K. pneumoniae, when compared to each site's method for phenotypic AST. The total agreement by antibiotic class for both the E. coli and K. pneumoniae pathogens averaged 97% for aminoglycosides, 92% for fluoroquinolones, and 93% for cephalosporins. These data demonstrate that the Acuitas AMR Gene Panel and Acuitas Lighthouse informatics may have the potential to serve as a front-line diagnostic to reduce time to targeted therapy for urinary tract infections, reducing length of stay and mortality.